NSRX Nasus Pharma Ltd. Forecast, Technical & Fundamental Analysis
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions... Show more
NSRX is expected to report earnings to fall 39.47% to -23 cents per share on September 02
Q2'26
Est.
$-0.23
Q4'25
Beat
by $0.15
The last earnings report on February 25 showed earnings per share of -37 cents, beating the estimate of -52 cents. With 5.74K shares outstanding, the current market capitalization sits at 35.48M.
NSRX's Stochastic Oscillator remains in overbought zone for 1 day
Expect a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
NSRX moved below its 50-day moving average on July 31, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NSRX crossed bearishly below the 50-day moving average on July 17, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NSRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NSRX broke above its upper Bollinger Band on July 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on July 29, 2026. You may want to consider a long position or call options on NSRX as a result. In of 21 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for NSRX just turned positive on July 29, 2026. Looking at past instances where NSRX's MACD turned positive, the stock continued to rise in of 11 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NSRX advanced for three days, in of 32 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 18 cases where NSRX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.821) is normal, around the industry mean (19.378). NSRX has a moderately low P/E Ratio (0.000) as compared to the industry average of (26.213). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.974). NSRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). NSRX's P/S Ratio (0.000) is slightly lower than the industry average of (4.132).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NSRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NSRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock worse than average.
